Browse recruiting and upcoming clinical trials for multiple system atrophy.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this listHide
ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
Who can join AIAdults aged 30–70 with clinically probable, clinically established, or pathologically confirmed Multiple System Atrophy — parkinsonian subtype (MSA‑P).
What is being studied AITests safety, tolerability, and preliminary efficacy of a single intracerebral NouvNeu001 injection.
Who can join AIPeople aged 19–70 with chronic spinal cord injury (complete motor paralysis at/above T6) or parkinsonian multiple system atrophy with orthostatic hypotension.
What is being studied AIWhether home-based transcutaneous spinal cord stimulation (SCONE device) is safe and feasible for orthostatic hypotension.
Who can join AIPeople over 18 and under 80 with MSA‑P or Parkinson disease who have orthostatic hypotension and take levodopa with carbidopa or benserazide.
What is being studied AITests how carbidopa:levodopa ratio affects standing blood-pressure drops (orthostatic hypotension).
Who can join AIPeople with Parkinson's disease or related movement disorders, including progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, vascular Parkinsonism, orthostatic tremor, dystonia, and tremor disorders.
What is being studied AITests feasibility, safety, tolerability, and effects of the CUE1/CUE1+ wearable device on symptoms.
Who can join AIAdults aged 30–85 with progressive supranuclear palsy (PSP), multiple system atrophy (MSA), or corticobasal syndrome (CBS) who meet the study's diagnostic and testing requirements.
What is being studied AITests whether daily nicotinamide riboside affects disease progression and symptoms in atypical parkinsonism.
Who can join AIAdults 40–80 with autonomic failure (including pure autonomic failure, multiple system atrophy, or Parkinson disease) who have neurogenic orthostatic hypotension and nighttime supine hypertension.
What is being studied AITests effects of CPAP on supine (lying-down) high blood pressure and orthostatic blood pressure.
Who can join AIAdults 18–80 with primary autonomic failure (e.g., Multiple System Atrophy or Pure Autonomic Failure) and nocturnal supine hypertension (SBP ≥150 mmHg).
What is being studied AICompares nighttime abdominal heat versus sham for nocturnal supine systolic blood pressure.
Who can join AIPeople aged 18–80 with Alzheimer's disease, Parkinson's disease, Lewy body dementia, multiple system atrophy, frontotemporal dementia, or amyotrophic lateral sclerosis (ALS).
What is being studied AITests safety and preliminary efficacy of hUC-MSC-sEV-001 nasal drops in several neurodegenerative diseases.
Who can join AIHealthy adults and people with Alzheimer dementia, ALS, Parkinson's or related movement disorders, DLB, or adult/very-late-onset psychotic disorders.
What is being studied AIUltra‑high‑resolution PET and MRI scans with multiple tracers to image small brain and spinal cord regions.
Who can join AIPeople aged 40–80 with multiple system atrophy, pure autonomic failure, or Parkinson disease who have neurogenic orthostatic hypotension.
What is being studied AITests how midodrine and droxidopa affect abdominal venous capacitance and stroke volume during head-up tilt.
Who can join AIPeople aged 50–75 with Parkinson disease or related parkinsonian syndromes (PD, MSA, PSP, CBD, DLB, vascular or drug‑induced parkinsonism).
What is being studied AITests AI-analyzed motor recordings with levodopa challenge to find diagnostic cut-offs and digital biomarkers.
Who can join AIAdults (age 35 or older) with PSP, corticobasal syndrome/degeneration (CBS/CBD), or multiple system atrophy (MSA), and unaffected family members of affected people.
What is being studied AICollects blood for research whole-genome sequencing and confirms possibly related findings with CLIA testing.
Who can join AIPeople with neurodegenerative diseases or cognitive impairment (e.g., Parkinson disease, Alzheimer disease, Lewy body disease, MSA, ALS).
What is being studied AICollects clinical, movement, imaging, EEG, voice, microbiota, and blood data for marker discovery.
Who can join AIPeople aged 30 days or older who have one of the listed conditions (for example ALS, Alzheimer disease, Parkinson disease, MS, diabetes, certain reproductive cancers, or PTSD) or who serve as healthy controls.
What is being studied AICollects blood, skin, and saliva to make stem cells, run genetic tests, and store samples.
Who can join AIPeople with Alzheimer Disease, Dementia With Lewy Bodies, Frontotemporal Dementia, Parkinson's Disease Dementia, or Multiple System Atrophy undergoing a lumbar puncture.
What is being studied AICollects cerebrospinal fluid to measure Alzheimer's biomarkers and build a clinical-CSF database.
Who can join AIAdults (18+) with neurodegenerative diseases, including MSA, Parkinson disease, PSP, motor neuron disease, or other neurodegenerative disorders.
What is being studied AICollects FEES laryngeal exam results, laryngeal EMG if available, and swallowing questionnaires.
Who can join AIAdults (18+) with possible or probable multiple system atrophy who are patients in the UT Southwestern MSA clinic and can attend the multidisciplinary clinic every four months.
What is being studied AICollects patient and caregiver questionnaires to study MSA burden and clinic care effects.
Who can join AIAdults (18+) with synucleinopathies or related autonomic disorders such as PD, DLB, MSA, PAF, neurogenic orthostatic hypotension, or RBD.
What is being studied AICollects clinical data and biological markers to map progression of synucleinopathies.
Who can join AIPeople with Parkinson's disease, Parkinsonism (including Multiple System Atrophy and Progressive Supranuclear Palsy), mild cognitive impairment, and healthy volunteers.
What is being studied AITests topographical (navigational) and visuospatial (reaching) memory with gait and eye-tracking measures.
Who can join AIAdults with confirmed idiopathic REM Sleep Behavior Disorder, and matched healthy volunteers. (People who already have Parkinson disease, dementia including Lewy body dementia, or multiple system atrophy are generally excluded.)
What is being studied AICollects clinical assessments, blood and lumbar puncture samples, brain imaging, and sleep studies to build biomarkers.
Who can join AIAdults (age 21+) with symptoms of neurodegenerative or related disorders, including PSP, CBD, PCA, LPA, FTD variants, MSA, and Parkinson disease.
What is being studied AICollects clinical data, imaging (MRI and PET), and blood for genetic studies.
Who can join AIPeople diagnosed with multiple system atrophy (MSA), dementia with Lewy bodies (DLB), progressive supranuclear palsy (PSP), or corticobasal degeneration (CBD).
What is being studied AICollects clinical and biomarker data to describe progression and imaging changes in atypical parkinsonian syndromes.
Who can join AIPeople with a clinical diagnosis of Parkinson's disease or clinically diagnosed/probable multiple system atrophy.
What is being studied AITests whether multimodal clinical, imaging, electrophysiology, biospecimen, and genetic data identify early biomarkers and subtypes.
Who can join AIPeople with various neurodegenerative diseases (Parkinson disease, MSA, PSP, Alzheimer's, MND, SVD, FTD) and age‑matched healthy controls.
What is being studied AICollects clinical, cognitive, questionnaire data and blood samples for biomarker and genetic study.
Trials that may include multiple system atrophy (2)
ClinicalTrials.gov returned these when we searched for this condition, but we could not confirm from the registry records that they are intended for people with it. Check each trial’s eligibility criteria, and ask the study team if you are unsure.